Alejandro González Veliz: Cardiology Enters the Era of Inflammation
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn:
“Cardiology is changing.
And inflammation may be one of the biggest reasons why.
For decades, cardiovascular risk was centered around:
- LDL cholesterol
- stenosis severity
- ischemia
But many patients continue to experience cardiovascular events despite ‘optimal’ lipid control.
Why?
Because atherosclerosis is not only a lipid disease.
It is also a chronic inflammatory disease.
Inflammation influences:
- endothelial dysfunction
- plaque formation
- plaque vulnerability
- thrombosis
- residual cardiovascular risk
This evolving paradigm is reshaping modern preventive cardiology.
Today, inflammation is increasingly connected to:
- hs-CRP
- obesity
- insulin resistance
- metabolic disease
- PCOS
- GLP-1 therapies
- residual inflammatory risk
The future of cardiovascular prevention may become far more personalized:
- ApoB
- Lp(a)
- inflammatory profiling
- metabolic health
- vascular biology
The question is no longer only:
‘How severe is the stenosis?’
The question is becoming:
‘How biologically active is the disease?’
Cardiology is entering the era of inflammation.”
Stay updated with Hemostasis Today.
-
May 18, 2026, 13:50Arshad-Ali Auhammad: Celebrating Youth Leadership in the Global Bleeding Disorders Community
-
May 18, 2026, 13:36Zain Khalpey: In Cardiovascular Medicine Flow Is Everything
-
May 18, 2026, 13:36George Adel: Advancing Stroke Management at El Mabara Hospital Through Collaborative ICU Engagement
-
May 18, 2026, 13:33Astha Thakkar: Three Things to Know Before Your IV Iron Infusion
-
May 18, 2026, 13:29Brian O Mahony: Ahead of the World Health Assembly in Geneva
-
May 18, 2026, 13:24Marian Galovic: When, Why and How to Perform an EEG After Stroke?
-
May 18, 2026, 13:23Behnood Bikdeli: A Wonderful Experience at the International Symposium on Thrombosis and Vessels
-
May 18, 2026, 13:16Wolfgang Miesbach: New Editorial Highlights – 6 Year Outcomes of Hemophilia B Gene Therapy
-
May 18, 2026, 13:10Ritika Jankar: Hemophilia Market Size to Reach USD 23.46 Billion by 2035